Inovio’s Positive Zika Vaccine Study Data Published in New England Journal of Medicine

Inovio Pharmaceuticals, Inc. {NASDAQ:INO} reported today on positive safety and immune response results from a first-in-man, multi-center phase 1 trial of a vaccine against the Zika virus.

The phase 1 trial of Inovio’s DNA-based Zika vaccine (GLS-5700) induced high levels of binding antibodies in 100% of participants. Continue reading